When to consider liver transplantation in hepatocellular carcinoma patients?

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2017-01-01 Epub Date: 2017-07-06 DOI:10.2217/hep-2016-0010

Ka Wing Ma, Tan To Cheung

引用次数: 0

Abstract

Orthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed.

查看原文本刊更多论文

肝细胞癌患者何时考虑肝移植？

异位肝移植（LT）一直被认为是三种治愈性治疗方式中最好的一种。然而，肝细胞癌（HCC）患者何时考虑肝移植仍是一个复杂的临床问题。在本文中，我们将探讨肝细胞癌LT治疗的最新进展，包括正位LT（原发性或挽救性LT）的时机、患者选择标准、更新的预后指标和评分系统、降期和桥接治疗、挽救性LT以及LT后肝细胞癌复发的治疗方案。此外，还将讨论免疫抑制疗法的演变以及LT治疗HCC的未来发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.